Navigation Links
New data showed Actos prevented progression of atherosclerotic plaque volume in patients
Date:3/31/2008

Chicago, IL, March 31, 2008 New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS® (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial.

The PERISCOPE trial was presented today as a late breaker at the 57th Annual Scientific Session of the American College of Cardiology in Chicago. This trial adds to the body of cardiovascular data for ACTOS. ACTOS studies, conducted over the past 10 years in more than 16,000 patients, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

We are pleased with the results of the PERISCOPE, which further expands our cardiovascular data with ACTOS, said David P. Recker, M.D., senior vice president, Clinical Sciences and interim president at Takeda Global Research & Development. While not definitive, data from PERISCOPE combined with results from a previous study, looking at surrogate endpoints, have shown a consistent trend toward decreasing cardiovascular risk by reducing the atherosclerotic burden in people with type 2 diabetes.

PERISCOPE is the first clinical trial to examine the effects of an oral antidiabetic medication on the development of coronary atherosclerosis in patients with type 2 diabetes using IVUS technology. The trial conducted in 97 centers in the U.S., Canada and Latin America with 543 patients, used IVUS imaging of the coronary arteries. The analysis demonstrated a statistically significant difference in percent change in coronary artery atheroma volume in favor of ACTOS treatment compared to glimepiride treatment.

The data showed that patients treated with glimepiride, a sulfonylurea and commonly used diabetes medication, exhibited progression of coronary atherosclerosis. In contrast, the ACTOS arm showed no progression of coronary atherosclerosis over the 18-month period from the initial baseline measurement.

Cardiovascular safety data was collected by looking at macrovascular events and episodes of congestive heart failure (CHF). The number of episodes of a common cardiovascular endpoint of cardiovascular mortality, non-fatal MI, or non-fatal stroke was 6 (2.2%) in glimepiride patients and 5 (1.9%) in ACTOS-treated patients. The number of hospitalizations due to CHF was equivalent in both arms. In the ACTOS-treated group, eight patients experienced a bone fracture, none involving the hip or spine.

Atherosclerosis is a condition that leads to reduced or blocked blood flow, and is accelerated in patients with type 2 diabetes. Atherosclerosis-related cardiovascular disease is the leading cause of death and disability in people with type 2 diabetes. Published data shows that slowed progression and reductions in atheroma volume lessens the incidence of a second heart attack. IVUS measures the volume of plaque build-up in the coronary arteries, a marker of coronary atherosclerosis.

The data are consistent with the findings of the CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne) trial. Both PERISCOPE and CHICAGO support the findings of the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) trial, which showed that ACTOS was not associated with an increased risk of heart attack, stroke or death.


'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
917-865-6688
Takeda Pharmaceuticals North America
Source:Eurekalert

Related medicine news :

1. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
2. Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
3. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
4. New study of Concerta showed significant improvement of ADHD symptom management in adults
5. African Americans at Risk for Low Calcium Intake - New Survey Finds Those Experiencing Symptoms of Lactose Intolerance May be Sidelining Dairy in Their Diets
6. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
7. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
8. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
9. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
10. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
11. One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... Biscuit”: a biographical account following a man who went on to support his country and ... born in Lynn Haven, Florida and at the age of 5, his family moved to ... joined the Navy and got married right out of boot camp. , He and ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers ... creation of published author, Gene Gaapf, a retired truck driver, and a long-time writer, ... writing since high school and have many different titles,” Gaapf mentions about his different ...
(Date:1/19/2017)... ... 2017 , ... Next week after January 20th, the fear for many is ... circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis at ... public servants were suppose to prioritize. Interviews provided below. , Among those ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... WhoHaha ... teaming up with the American Heart Association (AHA) to produce a three-part video series ... videos will debut as part of the launch of AHA’s Healthy For Good™ movement, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research ... Li completed his internship in internal medicine at the Emory University and dermatology ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017  Abaxis, Inc. (NasdaqGS: ABAX ... instruments and consumables for the medical and veterinary markets ... financial results for the third quarter fiscal year 2017, ... 4:15 p.m. ET on Thursday, January 26, 2017.  The ... fiscal year 2017 after the market closes on Thursday, ...
(Date:1/19/2017)... ViewRay, Inc. (Nasdaq: VRAY) announced today that the German Research ... Germany , has purchased a MRIdian Linac ... Heidelberg as part of its initiative for MRI-based radiation ... headed by Medical Director and Professor Jürgen Debus, M.D., ... Cancer Research Center (DKFZ), the Heidelberg Heavy Ion Center ...
(Date:1/19/2017)... -- Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, ...   Major research investment to work ...   The Milner Therapeutics Institute today announces ... partner to the Milner Therapeutics Consortium. Pfizer has agreed ... of materials between industry and academia and allocation of ...
Breaking Medicine Technology: